Class of warrant or right number of securities called by each warrant or right exercised.

No definition available.

Name:	pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised
Namespace Prefix:	pcvx_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of royalty payment on annual net sales of vaccine products for human health.

+ References

No definition available.

+ Details

Name:	pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth
Namespace Prefix:	pcvx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of royalty payment on net sales of vaccine compositions for animal health.

+ References

No definition available.

+ Details

Name:	pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth
Namespace Prefix:	pcvx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Date the warrants or rights are exercisable, in YYYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644

+ Details

Name:	us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

+ Details

Name:	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.

+ References

No definition available.

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_CommonStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of expense (income) related to adjustment to fair value of warrant liability.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section 25
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875

+ Details

Name:	us-gaap_FairValueAdjustmentOfWarrants
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

+ Details

Name:	us-gaap_RelatedPartyTransactionDueFromToRelatedParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name:	us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=pcvx_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=pcvx_SupplyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=pcvx_SeriesCRedeemableConvertiblePreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=pcvx_LicenseAmendmentATwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=pcvx_CommonStockWarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=pcvx_PreferredStockWarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Related Party Transactions - Additional Information (Details) - USD ($)		3 Months Ended		9 Months Ended
	May 29, 2018	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Common stock, shares owned		52,587,855		52,587,855		51,071,593
Warrant exercised							46,869
Change in fair value of redeemable convertible preferred stock warrant					$ 179,000
Sutro Biopharma, Inc
Related Party Transaction [Line Items]
Common stock, shares owned		1,600,000		1,600,000		1,600,000
Accrued expenses payable		$ 0		$ 0		$ 700,000
Sutro Biopharma, Inc \| License Agreement
Related Party Transaction [Line Items]
Percentage of royalty payment on annual net sales of vaccine products for human health		4.00%		4.00%
Percentage of royalty payment on net sales of vaccine compositions for animal health		2.00%		2.00%
Sutro Biopharma, Inc \| Supply Agreement
Related Party Transaction [Line Items]
Expenses related to agreement		$ 0	$ 100,000	$ 2,400,000	300,000
Sutro Biopharma, Inc \| Series C Redeemable Convertible Stock
Related Party Transaction [Line Items]
Warrant to purchase shares of stock								59,276
Warrant purchase price per share								$ 11.5215
Sutro Biopharma, Inc \| Series C Redeemable Convertible Stock \| License Amendment A2
Related Party Transaction [Line Items]
Warrant to purchase shares of stock	59,276
Warrant purchase price per share	$ 11.5215
Warrant exercisable and vests immediately and expires date	May 29, 2018
Sutro Biopharma, Inc \| Common Stock
Related Party Transaction [Line Items]
Warrant to purchase shares of stock								31,857
Warrant purchase price per share								$ 0.79289
Sutro Biopharma, Inc \| Common Stock Warrant
Related Party Transaction [Line Items]
Warrant exercised							30,278
Sutro Biopharma, Inc \| Preferred Stock Warrant
Related Party Transaction [Line Items]
Warrant exercised							16,591
Change in fair value of redeemable convertible preferred stock warrant		$ 0	$ 0	$ 0	$ 200,000